Triple therapy for asthma reviewed

Does single inhaler triple therapy pose a potential quality use of medicines issue? At its April 2025 meeting, the Drug Utilisation Sub-Committee reviewed the utilisation of several single inhaler therapies for the treatment of severe asthma. These included fluticasone furoate + umeclidinium + vilanterol, beclomethasone + formoterol + glycopyrronium and mometasone + indacaterol + glycopyrronium.